These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 16514315)

  • 1. Transient neuropathy after needle-free injection outside of recommended sites.
    Harris M; Larsen G; Valyi M; Walker E; Montaner JS
    AIDS; 2006 Mar; 20(5):784-5. PubMed ID: 16514315
    [No Abstract]   [Full Text] [Related]  

  • 2. Needle-free Fuzeon in works.
    AIDS Patient Care STDS; 2005 Sep; 19(9):614. PubMed ID: 16164388
    [No Abstract]   [Full Text] [Related]  

  • 3. Alternative administration options for Fuzeon.
    AIDS Patient Care STDS; 2007 Nov; 21(11):891. PubMed ID: 18338434
    [No Abstract]   [Full Text] [Related]  

  • 4. An open-label safety study of enfuvirtide injection with a needle-free injection device or needle/syringe: the Biojector 2000 Open-label Safety Study (BOSS).
    Lalezari JP; Saag M; Walworth C; Larson P
    AIDS Res Hum Retroviruses; 2008 Jun; 24(6):805-13. PubMed ID: 18507525
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enfuvirtide plasma levels and injection site reactions using a needle-free gas-powered injection system (Biojector).
    Harris M; Joy R; Larsen G; Valyi M; Walker E; Frick LW; Palmatier RM; Wring SA; Montaner JS
    AIDS; 2006 Mar; 20(5):719-23. PubMed ID: 16514302
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enfuvirtide: patient acceptance and strategies for managing injection-site reactions.
    Rice C; Wilantewicz H
    AIDS Read; 2006 Sep; 16(9):470-4, 490-1. PubMed ID: 17024766
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enfuvirtide doubles chances for suppression.
    AIDS Patient Care STDS; 2004 Sep; 18(9):550. PubMed ID: 15630779
    [No Abstract]   [Full Text] [Related]  

  • 8. [Combined treatment with fusion inhibitor. HIV-1 viruses under control longer].
    MMW Fortschr Med; 2004 Apr; 146(15):68. PubMed ID: 15373030
    [No Abstract]   [Full Text] [Related]  

  • 9. The optimal use of enfuvirtide.
    Gallant JE
    Hopkins HIV Rep; 2003 May; 15(3):1-3. PubMed ID: 12809103
    [No Abstract]   [Full Text] [Related]  

  • 10. European Commission approves Fuzeon following FDA approval--first HIV-fusion inhibitor in fight against HIV.
    Infection; 2003 Aug; 31(4):7-8. PubMed ID: 14562955
    [No Abstract]   [Full Text] [Related]  

  • 11. Pharmacokinetic bioequivalence of enfuvirtide using a needle-free device versus standard needle administration.
    True AL; Chiu YY; Demasi RA; Stout R; Patel I
    Pharmacotherapy; 2006 Dec; 26(12):1679-86. PubMed ID: 17125431
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fuzeon: avoiding injection-site reactions.
    AIDS Treat News; 2006; (421):5. PubMed ID: 17405216
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Enfuvirtide].
    Gerstoft J
    Ugeskr Laeger; 2004 Nov; 166(48):4355-7. PubMed ID: 15587625
    [No Abstract]   [Full Text] [Related]  

  • 14. T-1249 development suspended.
    Huff B
    GMHC Treat Issues; 2003 Dec; 17(12):6. PubMed ID: 15011643
    [No Abstract]   [Full Text] [Related]  

  • 15. Short communication safety, tolerability and pharmacokinetics of enfuvirtide administered by a needle-free injection system compared with subcutaneous injection.
    Gottlieb M; Thommes JA;
    Antivir Ther; 2008; 13(5):723-7. PubMed ID: 18771056
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enfuvirtide: a new class of antiretroviral therapy for HIV infection.
    Leao JC; Frezzini C; Porter S
    Oral Dis; 2004 Nov; 10(6):327-9. PubMed ID: 15533206
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enfuvirtide access, administration, and patient education.
    Celano SA
    Hopkins HIV Rep; 2003 May; 15(3):1, 12. PubMed ID: 12809102
    [No Abstract]   [Full Text] [Related]  

  • 18. Analysis of a switch from enfuvirtide to raltegravir in patients with undetectable viral load: efficacy and quality of life at 24 weeks.
    Sayana S; Prosser P; Ricaurte JC; Sanchez S; Hamwi G; Hershey-Weber J; Chien C; Easley A; Nguyen T; Wilson L; Khanlou H
    J Int Assoc Physicians AIDS Care (Chic); 2009; 8(2):85-6. PubMed ID: 19369697
    [No Abstract]   [Full Text] [Related]  

  • 19. A randomized study to evaluate injection site reactions using three different enfuvirtide delivery mechanisms (the OPTIONS study).
    Boyd MA; Truman M; Hales G; Anderson J; Dwyer DE; Carr A
    Antivir Ther; 2008; 13(3):449-53. PubMed ID: 18572758
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The importance of sequencing in treatment options.
    Berger DS
    Posit Aware; 2001; 12(3):42-3. PubMed ID: 11686121
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.